Loading stock data…
Immunovant (IMVT)
$39.57+0.32 (+0.82%)
Market ClosedLast close Sep 8
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immunovant, Inc. in the Healthcare sector is trading at $39.57 with a market capitalization of $6.8B. Wall Street consensus targets $48.88 (16 analysts), implying a +23.5% move over the next 12 months. The stock is currently near its 52-week high of $45.42, remaining 29.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 21 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 21) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$159.55M↓ | -$114.36M↑ | -$131.76M↓ | -$127.22M↓ | -$113.83M |
| Net Income | -$147.86M↓ | -$110.64M↑ | -$126.50M↓ | -$120.61M↓ | -$106.45M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating pol...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.82B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-59.30%
Volume
Today's trading volume
1.51M
Recent News
Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says
Immunovant (IMVT) has broad diversification with encouraging updates but faces balanced risk/reward
Immunovant (IMVT) Q1 2027 Earnings Call Transcript
CEO signals multiple pivotal data readouts ahead as cash runway supports IMVT-1402 development.
Roivant Sciences Q1 Earnings Call Highlights
Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie
Immunovant, Inc. Q1 2027 Earnings Call Summary
Moby summary of Immunovant, Inc.'s Q1 2027 earnings call
Immunovant Q1 Earnings Call Highlights
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant (NASDAQ:IMVT). Chief Executive Officer Matt